Some cancer cells play dead to dodge treatment — but scientists may have found a way to flip them back on. ETH Zurich researchers developed a light-controlled molecular switch that destroys the receptors keeping tumor cells dormant. Tested in lung cancer cells, the approach successfully roused sleeping tumors while sparing healthy tissue, opening a promising new path for precision cancer therapy.
Some cancer cells survive treatment not by fighting back, but by going to sleep. Triggered by stress hormones, these dormant tumor cells slow their growth dramatically, making them nearly invisible to many cancer drugs. ETH Zurich scientists have now developed a clever molecular switch that could wake them up — and make them vulnerable again.
The switch works by hijacking the cell's own protein recycling system. It's designed to tag glucocorticoid receptors — the proteins that push cancer cells into dormancy — for destruction. The twist: expose the switch to a specific wavelength of light, and it bends, halting the process. This means researchers can inject the switch into a tumor and then use light to protect surrounding healthy tissue, keeping the destructive effect confined to the cancer.
In lab cultures of lung cancer cells, the system rapidly broke down glucocorticoid receptors, and gene activity confirmed the cells exited their dormant state. Animal studies are the next step.
Key Takeaways:
Why it matters: Tumor dormancy is one of the biggest reasons cancers relapse after treatment. A tool that can selectively wake and then eliminate these hidden cells could fundamentally change how we treat stubborn, treatment-resistant cancers.
